TARS רווח עתידי Tarsus Pharmaceuticals Inc

סמל ולוגו של המותג tarsusrx.com (TARS)

Tarsus Pharmaceuticals (TARS) is cementing Inertia's status as the standard of care for ocular infections, creating a steady cash flow. The synthesis process for the drops is AI-automated, although the clinical application requires physician oversight. The primary challenge remains the pace of the flagship product's commercial rollout. The value of 0.02 aligns with the current metric shown in the analytical profit forecast.

TARS: תחזית רווחי החברה Tarsus Pharmaceuticals 26.02.2025 - 16.11.2026

Tarsus Pharma (TARS) - פילוחי מדדים ודוחות פיננסיים

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח פונדמנטלי של החברה:Tarsus Pharmaceuticals Inc, TARS
מוצרים מוגמרים של Tarsus Pharmaceuticals Inc

This indicator reflects the discounted value of expected cash flows, recalculating the business's potential income via the weighted average cost of capital to determine fair value. By analyzing the forward profitability trend, the investor sees the market valuation of Tarsus Pharmaceuticals (TARS), which is supported by the stability of the US domestic market and the absence of geopolitical barriers in the ophthalmology drug sector.